- radionuclide targeted therapies (NET, lymphoma, thyrotoxicosis, bone metastases, thrombocytosis)
- PET/CT imaging
- SPECT, SPECT/CT imaging
- diagnostic and therapeutic nuclear medicine
Dr Du has both a private and an NHS practice at The Royal Marsden.
Dr Yong Du graduated from Shandong Medical University. He was awarded a PhD in Cancer Sciences at University of Southampton for his work on lymphoma and completed his nuclear medicine specialist training at the Institute of Nuclear Medicine, University College Hospital in London. He was the first recipient of the national HEFCE Clinical Senior Lectureship Award in the Nuclear Medicine specialty (awarded in June 2009). He was appointed as a Consultant in Nuclear Medicine and PET/CT imaging at The Royal Marsden in 2011.
In conjunction with his clinical practice, he has research interests to further assess the role, efficacy and limitations of PET/CT in various cancers, so as to optimise its use and inform tailored treatments for individual patients. Dr Yong Du also has extensive experience in radionuclide targeted therapy. He is interested in combining the fast advancing functional imaging technology with multidisciplinary expertise to help develop and optimise radionuclide targeted therapy for cancer patients.
In collaboration with researchers across the country, Dr Yong Du has led and contributed to a number of international and national studies, has published first-authored research papers in high-impact oncology journals including Journal of Clinical Oncology, Blood and Cancer Research.
Dr Yong Du serves at a number of international and national medical committees including the French AERES committee, the NCRI PET Research Network and the NCRI Clinical and Translational Radiotherapy (CTRad) Research Working Group.